Sarepta is also going way outside of antisense therapies to find treatment for DMD - CRISPR, gene therapy, utrophin modulation - they already have 6 clinical trials underway.
Heap of companies now in the DMD space really not sure how much room is left there for johnny come latelys even if ANP end up starting a trial - $1B market to a very small population.
Surely the company is better off trying to take one of the other drugs they've spent years trying to sell off further rather than another diversion.
600%, page-32
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.002(1.88%) |
Mkt cap ! $70.77M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 8.0¢ | 7.7¢ | $30.92K | 388.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125000 | 7.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 126337 | 6 |
View Market Depth
| Last trade - 13.50pm 12/08/2024 (20 minute delay) ? |
| PER (ASX) Chart |